Get more information about the current state of gout research.

Sign Up Now

Do Oral ULTs Reach Goal?

Percentage of patients treated with febuxostat and allopurinol who reached target sUA level2,6

The pooled phase 3 results for the percentage of patients with an sUA level of <6 mg/dL at the final visit for febuxostat 80 mg was 65% and for allopurinol 300 mg was 40%.7,8

If patients fail to reach sUA target levels <6 mg/dL on oral ULTs at maximum medically appropriate doses and continue to have frequent gout flares (>2 flares/year) or nonresolving tophi, gout remains uncontrolled.9

sUA, serum uric acid.

A chart displaying the percentage of patients with an sUA level of less than 6mg/dL for febuxostat 80 mg and allopurinol 300 mg in a 52-week clinical trial, with 53% of FEB recipients (n=256) and 21% of ALLO recipients (n=253) reaching the primary endpoint: <6.0 at last 3 monthly measurements, 47% of FEB and 13% of ALLO <5.0 at final visit, and 20% of FEB and 2% of ALLO <4.0 at final visit in post hoc analysis A chart displaying the percentage of patients with an sUA level of less than 6mg/dL for febuxostat 80 mg and allopurinol 300 mg in a 52-week clinical trial, with 53% of FEB recipients (n=256) and 21% of ALLO recipients (n=253) reaching the primary endpoint: <6.0 at last 3 monthly measurements, 47% of FEB and 13% of ALLO <5.0 at final visit, and 20% of FEB and 2% of ALLO <4.0 at final visit in post hoc analysis

*Post hoc analysis.

References

  1. Schumacher HR Jr, et al. Arthritis Rheum. 2008;59(11):1540-1548.
  2. Becker MA, et al. N Engl J Med. 2005;353(23):2450-2461.
  3. Becker MA, et al. Semin Arthritis Rheum. 2015;45(2):174-183.
  4. Perez-Ruiz F. Rheumatology (Oxford). 2009;48(suppl 2):ii9-ii14.
  5. Shoji A, et al. Arthritis Rheum. 2004;51(3):321-325.
  6. Uloric. Prescribing Information. Takeda Pharmaceuticals Inc, 2019.
  7. Cutolo M, et al. Eur Rev Med Pharmacol Sci. 2017;21(18):4186-4195.
  8. Garcia-Valladares I, et al. Ther Adv Musculoskel Dis. 2011;3(5):245-253.
  9. FitzGerald JD, et al. Arthritis Care Res (Hoboken). 2020;72(6):744-760.